Jolien Ke Veraart

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Journal of Psychopharmacology April 25, 2025 Jolien Ke Veraart, Sanne Y Smith-Apeldoorn, Annemarie van der Meij et al. 6 citations

Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...